112 related articles for article (PubMed ID: 19114305)
1. 3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.
Scott DA; Bell KJ; Campbell CT; Cook DJ; Dakin LA; Del Valle DJ; Drew L; Gero TW; Hattersley MM; Omer CA; Tyurin B; Zheng X
Bioorg Med Chem Lett; 2009 Feb; 19(3):701-5. PubMed ID: 19114305
[TBL] [Abstract][Full Text] [Related]
2. Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.
Scott DA; Balliet CL; Cook DJ; Davies AM; Gero TW; Omer CA; Poondru S; Theoclitou ME; Tyurin B; Zinda MJ
Bioorg Med Chem Lett; 2009 Feb; 19(3):697-700. PubMed ID: 19112018
[TBL] [Abstract][Full Text] [Related]
3. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
Scott DA; Dakin LA; Del Valle DJ; Diebold RB; Drew L; Gero TW; Ogoe CA; Omer CA; Repik G; Thakur K; Ye Q; Zheng X
Bioorg Med Chem Lett; 2011 Mar; 21(5):1382-4. PubMed ID: 21295474
[TBL] [Abstract][Full Text] [Related]
4. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors.
Ioannidis S; Lamb ML; Almeida L; Guan H; Peng B; Bebernitz G; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1669-73. PubMed ID: 20144546
[TBL] [Abstract][Full Text] [Related]
5. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
Guay D; Boulet L; Friesen RW; Girard M; Hamel P; Huang Z; Laliberté F; Laliberté S; Mancini JA; Muise E; Pon D; Styhler A
Bioorg Med Chem Lett; 2008 Oct; 18(20):5554-8. PubMed ID: 18835163
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of novel anilinoquinolines as c-fms inhibitors.
Smalley TL; Chamberlain SD; Mills WY; Musso DL; Randhawa SA; Ray JA; Samano V; Frick L
Bioorg Med Chem Lett; 2007 Nov; 17(22):6257-60. PubMed ID: 17870531
[TBL] [Abstract][Full Text] [Related]
7. Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507.
Scott DA; Dakin LA; Daly K; Del Valle DJ; Diebold RB; Drew L; Ezhuthachan J; Gero TW; Ogoe CA; Omer CA; Redmond SP; Repik G; Thakur K; Ye Q; Zheng X
Bioorg Med Chem Lett; 2013 Aug; 23(16):4591-6. PubMed ID: 23842474
[TBL] [Abstract][Full Text] [Related]
8. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
Li Y; Liang J; Siu T; Hu E; Rossi MA; Barnett SF; Defeo-Jones D; Jones RE; Robinson RG; Leander K; Huber HE; Mittal S; Cosford N; Prasit P
Bioorg Med Chem Lett; 2009 Feb; 19(3):834-6. PubMed ID: 19097777
[TBL] [Abstract][Full Text] [Related]
9. Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
Scott DA; Aquila BM; Bebernitz GA; Cook DJ; Dakin LA; Deegan TL; Hattersley MM; Ioannidis S; Lyne PD; Omer CA; Ye M; Zheng X
Bioorg Med Chem Lett; 2008 Sep; 18(17):4794-7. PubMed ID: 18694641
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors.
El-Gamal MI; Al-Ameen SK; Al-Koumi DM; Hamad MG; Jalal NA; Oh CH
J Med Chem; 2018 Jul; 61(13):5450-5466. PubMed ID: 29293000
[TBL] [Abstract][Full Text] [Related]
11. Strategies for the design of selective protein kinase inhibitors.
Sawa M
Mini Rev Med Chem; 2008 Oct; 8(12):1291-7. PubMed ID: 18855742
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Becknell NC; Dandu RR; Lyons JA; Aimone LD; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(1):186-9. PubMed ID: 22153342
[TBL] [Abstract][Full Text] [Related]
14. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
[TBL] [Abstract][Full Text] [Related]
15. Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG.
Huang SC; Adhikari S; Afroze R; Brewer K; Calderwood EF; Chouitar J; England DB; Fisher C; Galvin KM; Gaulin J; Greenspan PD; Harrison SJ; Kim MS; Langston SP; Ma LT; Menon S; Mizutani H; Rezaei M; Smith MD; Zhang DM; Gould AE
Bioorg Med Chem Lett; 2016 Feb; 26(4):1156-60. PubMed ID: 26804230
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
Sasaki T; Takahashi T; Nagase T; Mizutani T; Ito S; Mitobe Y; Miyamoto Y; Kanesaka M; Yoshimoto R; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4232-6. PubMed ID: 19520574
[TBL] [Abstract][Full Text] [Related]
17. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
[TBL] [Abstract][Full Text] [Related]
18. 2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Owen DR; Rodriguez-Lens M; Corless MD; Gaulier SM; Horne VA; Kinloch RA; Maw GN; Pearce DW; Rees H; Ringer TJ; Ryckmans T; Stammen BL
Bioorg Med Chem Lett; 2009 Mar; 19(6):1702-6. PubMed ID: 19231185
[TBL] [Abstract][Full Text] [Related]
19. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution.
Blum CA; Zheng X; Brielmann H; Hodgetts KJ; Bakthavatchalam R; Chandrasekhar J; Krause JE; Cortright D; Matson D; Crandall M; Ngo CK; Fung L; Day M; Kershaw M; De Lombaert S; Chenard BL
Bioorg Med Chem Lett; 2008 Aug; 18(16):4573-7. PubMed ID: 18662872
[TBL] [Abstract][Full Text] [Related]
20. Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.
Patch RJ; Brandt BM; Asgari D; Baindur N; Chadha NK; Georgiadis T; Cheung WS; Petrounia IP; Donatelli RR; Chaikin MA; Player MR
Bioorg Med Chem Lett; 2007 Nov; 17(22):6070-4. PubMed ID: 17904845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
